Calcium antagonists in the treatment of experimental cerebral ischemia

Myron Ginsberg, B. Lin, E. Morikawa, W. Dalton Dietrich, R. Busto, M. Y T Globus

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Calcium ion functions widely as an intracellular messenger and regulator. Intracellular calcium dyshomeostasis occurs during hypoxic/ischemic cell injury, and pharmacological antagonism of calcium entry into neurons has been considered to be of potential therapeutic value. Calcium antagonists, in addition, tend to improve cerebral perfusion of both the normal and abnormal (post-ischemic) brain. Studies of these agents have shown variable degrees of cerebroprotection in focal and global ischemia models. (S)-Emopamil is a phenylalkylamine-type calcium channel blocker which also exhibits stereoselective antagonism of the serotonin S2 receptor and has excellent blood-brain barrier penetrability. Protection of hippocampal CA1 neurons has been demonstrated with pre-ischemic administration of (S)-emopamil in global ischemia models. Our laboratory has compared the efficacy of pre- vs. post-ischemic (S)-emopamil treatment on neuronal necrosis resulting from 10 min of transient normothermic global ischemia in the rat. (S)-Emopamil pre-treatment, 20 mg/kg i.p., 30 min prior to ischemia, with a second dose 2.5 h later, resulted in 1.8-2.4 fold increases in numbers of surviving CA1 pyramidal neurons. Post-ischemic administration was ineffective. Intracerebral microdialysis has revealed a partial attenuation of dopamine release with pre-ischemic (S)-emopamil administration. In focal cerebral ischemia (middle cerebral artery occlusion in the rat), our laboratory has demonstrated a marked reduction in cortical infarct volume with (S)-emopamil pre- or post-treatment. In additional studies in Sprague-Dawley rats with permanent MCA occlusion plus transient hypotension we have confirmed a 52% mean reduction in cortical infarct volume in 1-h post-treated rats; a trend toward reduced infarct volume when treatment was deferred to 2 h; but absence of an effect with initiation of treatment at 3 h. Thus, a temporal window for therapeutic efficacy may exist in focal infarction, lying between 1 and 2 h.

Original languageEnglish
Pages (from-to)334-337
Number of pages4
JournalArzneimittel-Forschung/Drug Research
Volume41
Issue number3 A
StatePublished - Jan 1 1991

Fingerprint

Brain Ischemia
Calcium
Rats
Ischemia
Neurons
Serotonin 5-HT2 Receptors
Pyramidal Cells
Middle Cerebral Artery Infarction
Microdialysis
Calcium Channel Blockers
Blood-Brain Barrier
Hypotension
Infarction
Sprague Dawley Rats
emopamil
Dopamine
Brain
Necrosis
Perfusion
Pharmacology

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Calcium antagonists in the treatment of experimental cerebral ischemia. / Ginsberg, Myron; Lin, B.; Morikawa, E.; Dalton Dietrich, W.; Busto, R.; Globus, M. Y T.

In: Arzneimittel-Forschung/Drug Research, Vol. 41, No. 3 A, 01.01.1991, p. 334-337.

Research output: Contribution to journalArticle

Ginsberg, Myron ; Lin, B. ; Morikawa, E. ; Dalton Dietrich, W. ; Busto, R. ; Globus, M. Y T. / Calcium antagonists in the treatment of experimental cerebral ischemia. In: Arzneimittel-Forschung/Drug Research. 1991 ; Vol. 41, No. 3 A. pp. 334-337.
@article{767e23c7feb84f6abd596772a40ceb43,
title = "Calcium antagonists in the treatment of experimental cerebral ischemia",
abstract = "Calcium ion functions widely as an intracellular messenger and regulator. Intracellular calcium dyshomeostasis occurs during hypoxic/ischemic cell injury, and pharmacological antagonism of calcium entry into neurons has been considered to be of potential therapeutic value. Calcium antagonists, in addition, tend to improve cerebral perfusion of both the normal and abnormal (post-ischemic) brain. Studies of these agents have shown variable degrees of cerebroprotection in focal and global ischemia models. (S)-Emopamil is a phenylalkylamine-type calcium channel blocker which also exhibits stereoselective antagonism of the serotonin S2 receptor and has excellent blood-brain barrier penetrability. Protection of hippocampal CA1 neurons has been demonstrated with pre-ischemic administration of (S)-emopamil in global ischemia models. Our laboratory has compared the efficacy of pre- vs. post-ischemic (S)-emopamil treatment on neuronal necrosis resulting from 10 min of transient normothermic global ischemia in the rat. (S)-Emopamil pre-treatment, 20 mg/kg i.p., 30 min prior to ischemia, with a second dose 2.5 h later, resulted in 1.8-2.4 fold increases in numbers of surviving CA1 pyramidal neurons. Post-ischemic administration was ineffective. Intracerebral microdialysis has revealed a partial attenuation of dopamine release with pre-ischemic (S)-emopamil administration. In focal cerebral ischemia (middle cerebral artery occlusion in the rat), our laboratory has demonstrated a marked reduction in cortical infarct volume with (S)-emopamil pre- or post-treatment. In additional studies in Sprague-Dawley rats with permanent MCA occlusion plus transient hypotension we have confirmed a 52{\%} mean reduction in cortical infarct volume in 1-h post-treated rats; a trend toward reduced infarct volume when treatment was deferred to 2 h; but absence of an effect with initiation of treatment at 3 h. Thus, a temporal window for therapeutic efficacy may exist in focal infarction, lying between 1 and 2 h.",
author = "Myron Ginsberg and B. Lin and E. Morikawa and {Dalton Dietrich}, W. and R. Busto and Globus, {M. Y T}",
year = "1991",
month = "1",
day = "1",
language = "English",
volume = "41",
pages = "334--337",
journal = "Drug Research",
issn = "2194-9379",
publisher = "Thieme",
number = "3 A",

}

TY - JOUR

T1 - Calcium antagonists in the treatment of experimental cerebral ischemia

AU - Ginsberg, Myron

AU - Lin, B.

AU - Morikawa, E.

AU - Dalton Dietrich, W.

AU - Busto, R.

AU - Globus, M. Y T

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Calcium ion functions widely as an intracellular messenger and regulator. Intracellular calcium dyshomeostasis occurs during hypoxic/ischemic cell injury, and pharmacological antagonism of calcium entry into neurons has been considered to be of potential therapeutic value. Calcium antagonists, in addition, tend to improve cerebral perfusion of both the normal and abnormal (post-ischemic) brain. Studies of these agents have shown variable degrees of cerebroprotection in focal and global ischemia models. (S)-Emopamil is a phenylalkylamine-type calcium channel blocker which also exhibits stereoselective antagonism of the serotonin S2 receptor and has excellent blood-brain barrier penetrability. Protection of hippocampal CA1 neurons has been demonstrated with pre-ischemic administration of (S)-emopamil in global ischemia models. Our laboratory has compared the efficacy of pre- vs. post-ischemic (S)-emopamil treatment on neuronal necrosis resulting from 10 min of transient normothermic global ischemia in the rat. (S)-Emopamil pre-treatment, 20 mg/kg i.p., 30 min prior to ischemia, with a second dose 2.5 h later, resulted in 1.8-2.4 fold increases in numbers of surviving CA1 pyramidal neurons. Post-ischemic administration was ineffective. Intracerebral microdialysis has revealed a partial attenuation of dopamine release with pre-ischemic (S)-emopamil administration. In focal cerebral ischemia (middle cerebral artery occlusion in the rat), our laboratory has demonstrated a marked reduction in cortical infarct volume with (S)-emopamil pre- or post-treatment. In additional studies in Sprague-Dawley rats with permanent MCA occlusion plus transient hypotension we have confirmed a 52% mean reduction in cortical infarct volume in 1-h post-treated rats; a trend toward reduced infarct volume when treatment was deferred to 2 h; but absence of an effect with initiation of treatment at 3 h. Thus, a temporal window for therapeutic efficacy may exist in focal infarction, lying between 1 and 2 h.

AB - Calcium ion functions widely as an intracellular messenger and regulator. Intracellular calcium dyshomeostasis occurs during hypoxic/ischemic cell injury, and pharmacological antagonism of calcium entry into neurons has been considered to be of potential therapeutic value. Calcium antagonists, in addition, tend to improve cerebral perfusion of both the normal and abnormal (post-ischemic) brain. Studies of these agents have shown variable degrees of cerebroprotection in focal and global ischemia models. (S)-Emopamil is a phenylalkylamine-type calcium channel blocker which also exhibits stereoselective antagonism of the serotonin S2 receptor and has excellent blood-brain barrier penetrability. Protection of hippocampal CA1 neurons has been demonstrated with pre-ischemic administration of (S)-emopamil in global ischemia models. Our laboratory has compared the efficacy of pre- vs. post-ischemic (S)-emopamil treatment on neuronal necrosis resulting from 10 min of transient normothermic global ischemia in the rat. (S)-Emopamil pre-treatment, 20 mg/kg i.p., 30 min prior to ischemia, with a second dose 2.5 h later, resulted in 1.8-2.4 fold increases in numbers of surviving CA1 pyramidal neurons. Post-ischemic administration was ineffective. Intracerebral microdialysis has revealed a partial attenuation of dopamine release with pre-ischemic (S)-emopamil administration. In focal cerebral ischemia (middle cerebral artery occlusion in the rat), our laboratory has demonstrated a marked reduction in cortical infarct volume with (S)-emopamil pre- or post-treatment. In additional studies in Sprague-Dawley rats with permanent MCA occlusion plus transient hypotension we have confirmed a 52% mean reduction in cortical infarct volume in 1-h post-treated rats; a trend toward reduced infarct volume when treatment was deferred to 2 h; but absence of an effect with initiation of treatment at 3 h. Thus, a temporal window for therapeutic efficacy may exist in focal infarction, lying between 1 and 2 h.

UR - http://www.scopus.com/inward/record.url?scp=0025969506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025969506&partnerID=8YFLogxK

M3 - Article

C2 - 1859503

AN - SCOPUS:0025969506

VL - 41

SP - 334

EP - 337

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 3 A

ER -